Medicamen Organics (NSE:MEDIORG) Total Receivables: ₹250.36 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MEDIORG Medicamen Organics Ltd NSE:MEDIORG
21 GF Score
Price ₹24.70
! 11 Warning Signs
View Full Analysis

What is Medicamen Organics Total Receivables?

Medicamen Organics NSE:MEDIORG -5.00% 21 Total Receivables is ₹250.36 Mil as of Mar. 2026. GuruFocus rates NSE:MEDIORG with a GF Score™ of 21/100. The stock has 11 warning signs investors should review.

Medicamen Organics's Total Receivables for the quarter that ended in Mar. 2026 was ₹250.36 Mil.

Medicamen Organics Total Receivables Related Terms

Medicamen Organics Total Receivables Historical Data

* Premium members only.

The historical data trend for Medicamen Organics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicamen Organics Total Receivables Chart

Medicamen Organics Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
Get a 7-Day Free Trial 62.45 107.68 167.00 258.52 250.36

Medicamen Organics Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Mar25 Mar26
Total Receivables Get a 7-Day Free Trial 107.68 137.44 167.00 258.52 250.36
NSE:MEDIORG
21GF Score
Medicamen Organics Ltd NSE:MEDIORG
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicamen Organics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹250.36 Mil mean?
Medicamen Organics (NSE:MEDIORG) has a Total Receivables of ₹250.36 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Medicamen Organics and its competitors.
Is Medicamen Organics' Total Receivables too high?
Medicamen Organics' current Total Receivables is ₹250.36 Mil. Overall, Medicamen Organics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' Total Receivables compare to ZTS and UTHR?
Medicamen Organics' Total Receivables of ₹250.36 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Medicamen Organics and its competitors. Medicamen Organics's current Total Receivables is ₹250.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current Total Receivables of ₹250.36 Mil. The current Total Receivables is ₹250.36 Mil. Medicamen Organics' overall GF Score™ is 21/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current Total Receivables is ₹250.36 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicamen Organics Business Description

Address Ashok Vihar Phase II, 10, Community Center No. 2, New Delhi, IND, 110052
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
21GF Score

Get the complete analysis for NSE:MEDIORG

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹24.70
Price